We provide a solution to democratization of genomic testing, making it a routine part of our healthcare, truly accessible to all, thus unlocking the door for implementation and optimisation of precision medicine therapies. 
Our technology enhances tissue profiling and enables informative liquid biopsies by allowing the analysis of challenging circulating biomarkers, including cell-free nucleic acids and exosomes.
Our first focus is in areas where patient need is high, market opportunity is significant, and our expertise is deep: molecular oncology, infective diseases, drug resistance.
Rosebio’s ZipArray platform offers a flexible and robust format for simultaneous and ultrasensitive detection of multiple and rare biomarkers, such as minority mutations, in single and often limited diagnostic samples. Our proprietary technology can be integrated within the existing laboratory infrastructure, without disruption of a diagnostic sample life cycle, and without high complexity operations or resources needed.
ZipArray allows easy integration and re-configuration of probes and protocols, aided by computational array design, responding to specific needs of existing and novel treatments, and assuring cutting-edge support to testing and implementation of molecular and biological drugs.

ROSEBIO

Org chart

Teams

Offices